The Cubs have traditionally taken a file-and-trial approach to arbitration, even though teams and players are free to reach ...

Terence Flynn, Biotech Analyst at Morgan Stanley, discusses Eli Lilly's recent stock boost and its designation as Morgan ...

In a report released today, Terence Flynn from Morgan Stanley reiterated a Buy rating on Eli Lilly & Co (LLY – Research Report), with a ...

Now, the Cubs can turn their focus to pitching. They need a little bit of help in their bullpen, even after acquiring Eli ...

Comparing Tyrzepatide and Semaglutide in the slimming drug market, with potential growth driven by increasing obesity rates worldwide. Explore more here.

The Guardians started the offseason with nine players eligible for arbitration. Steven Kwan and Lane Thomas are unsigned and ...

Now, it is certainly possible for players and teams who didn’t agreed to term by the 12 noon CT deadline to work out a deal ...

Chris Schott, an analyst from J.P. Morgan, maintained the Buy rating on Eli Lilly & Co (LLY – Research Report). The associated price target remains the same with $1,100.00. Discover the latest ...

Starting pitcher Matthew Boyd received a two-year deal in free agency and his Cleveland Guardians teammate, Eli Morgan, was acquired in a trade to bolster the bullpen. Still in the Roki Sasaki swe ...

The Series A funding round by the start-up, co-founded by executives of Aiolos Bio, the biotech that was sold to GSK last ...

Eli Lilly and Company (NYSE: LLY) will attend the 43rd Annual J.P. Morgan Healthcare Conference, Jan. 13-16, 2025. David A. Ricks, Lilly chair and CEO, will participate in a fireside chat on ...